BiotechTube

Abemaciclib + Aromatase Inhibitor + Abemaciclib + Fulvestrant

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hormone Receptor-positive Metastatic Breast Cancer

Conditions

Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer

Trial Timeline

Apr 27, 2022 → Apr 1, 2029

NCT ID
NCT05362760

About Abemaciclib + Aromatase Inhibitor + Abemaciclib + Fulvestrant

Abemaciclib + Aromatase Inhibitor + Abemaciclib + Fulvestrant is a approved stage product being developed by Eli Lilly for Hormone Receptor-positive Metastatic Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05362760. Target conditions include Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer.

What happened to similar drugs?

8 of 20 similar drugs in Hormone Receptor-positive Metastatic Breast Cancer were approved

Approved (8) Terminated (2) Active (12)
✅PEG-somatropinSun PharmaceuticalApproved
✅PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
✅Saizen® solution for injection (referred as Saizen®)MerckApproved
✅Saizen + SaizenMerckApproved
✅Zoledronic Acid + PlaceboNovartisApproved
✅somatropin + placeboNovo NordiskApproved
✅somatropinNovo NordiskApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05362760ApprovedRecruiting

Competing Products

20 competing products in Hormone Receptor-positive Metastatic Breast Cancer

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
40
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
26
Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing MouthwashDaiichi SankyoPhase 1
33
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
44
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open LabelAstellas PharmaPhase 3
44
Enzalutamide + PlaceboAstellas PharmaPhase 3
40
YM598Astellas PharmaPhase 2
27
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
35
PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropinSun PharmaceuticalPhase 3
40
ONO-4578 + letrozole + Palbociclib + abemaciclibOno PharmaceuticalPhase 1
33
Somatropin + SomatropinEli LillyPhase 3
40
Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent ChemotherapyEli LillyPhase 2
35
Somatropin + SomatropinEli LillyPhase 3
40
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
36
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
29
SHR7280Jiangsu Hengrui MedicinePhase 1
29